Natali _ Mis / Shutterstock.com
10 December 2024NewsAmericasLiz Hockley

Judge denies Intellia bid to throw out suit over $100m Regeneron pact

BlueAllele “plausibly alleged” that some of Intellia’s uses of technology were not reasonably related to FDA approval | Biotech claimed competitor received over $100m from Regeneron for using innovation to research therapeutic candidates.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
9 July 2024   Minnesota-based biotech firm says Intellia used its patented gene editing innovations | Regeneron paid Intellia $100m for R&D that infringed three patents, alleges BlueAllele.

More on this story

Biotechnology
9 July 2024   Minnesota-based biotech firm says Intellia used its patented gene editing innovations | Regeneron paid Intellia $100m for R&D that infringed three patents, alleges BlueAllele.

More on this story

Biotechnology
9 July 2024   Minnesota-based biotech firm says Intellia used its patented gene editing innovations | Regeneron paid Intellia $100m for R&D that infringed three patents, alleges BlueAllele.